BPC-157: A Deep Animal Record, A Thin Human File

The short version

BPC-157 stands for Body Protection Compound 157. It is a synthetic peptide fifteen amino acids long, copied from part of a protective protein found in human stomach juice. In animal studies — overwhelmingly rats — it appears to accelerate healing across multiple tissue types: tendons, the gut lining, muscle and nerve ^[5][6]. The most consistent explanation researchers give is that it promotes new blood-vessel growth into an injury, increasing the oxygen and nutrient supply repair depends on ^[4].

Here is the honest part. Almost all of this is animal evidence. As of 2025 reviews, only three small human pilot studies exist, and there are no large, rigorous human trials ^[2]. BPC-157 is not an approved drug anywhere, it is banned in sport by WADA, and popular online claims about weight loss or muscle building are not supported by published science ^[2]. This page summarizes what was studied; it is not advice and lists no human dose.

What it is

BPC-157 is a stable gastric pentadecapeptide — "pentadecapeptide" means a fifteen-amino-acid chain, and "stable gastric" reflects that the sequence comes from a cytoprotective protein in gastric juice and resists stomach-acid breakdown. Its amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (molecular formula C62H98N16O22), and it is catalogued under research designations PL 14736, PLD-116, and PL-10, and occasionally Bepecin. It is a synthetic research peptide, not a natural extract, and not an approved drug.

How it works

The best-characterized mechanism is angiogenesis — new blood-vessel formation. A 2017 study spanning a chick-membrane model, a rat hindlimb ischemia model, and human vascular endothelial cells showed that BPC-157 up-regulated VEGFR2 receptor expression and promoted its internalization, activating the downstream VEGFR2-Akt-eNOS pathway; blocking that internalization blocked the effect ^[4]. In plain terms: it appears to make blood-vessel cells more responsive to the body's own vessel-growth signal and accelerated blood-flow recovery in a model of blocked circulation ^[4].

Additional reported pathways include FAK-paxillin (cell migration), growth-hormone-receptor sensitization in tendon fibroblasts, and modulation of the nitric-oxide system. A 2016 review positions BPC-157 as a brain-gut-axis mediator affecting serotonergic and dopaminergic systems through Egr-1/NAB2, FAK-paxillin and JAK-2 pathways ^[7]. The picture is a peptide that nudges several repair-related signals in parallel rather than hitting a single target.

What the research shows

Foundational cytoprotection. The compound's name traces to its gut origins. In Wistar rats, BPC-157 reduced gastric-ulcer area and accelerated ulcer healing, with intramuscular delivery outperforming intragastric and ulcer-formation inhibition ratios of roughly 46-66% at higher doses ^[5].

Tendon. In a fully transected rat Achilles tendon, BPC-157 accelerated healing across biomechanical, functional, microscopic and macroscopic measures and stimulated tendocyte (tendon-cell) outgrowth in culture, with better collagen organization and restored tendon integrity versus untreated controls ^[6].

Pharmacokinetics. The first formal PK/ADME characterization, in rats and beagle dogs, found linear pharmacokinetics, a short elimination half-life under 30 minutes, modest intramuscular bioavailability (~14-19% in rats, ~45-51% in dogs), and rapid breakdown into small peptide fragments that re-enter normal amino-acid metabolism ^[3]. The intact peptide does not linger long in the bloodstream.

Human evidence. As of the current literature, it is genuinely small. A 2025 first-in-human intravenous safety pilot gave BPC-157 up to 20 mg to two healthy adults; it was well tolerated with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers — but the sample was two people and it was a safety pilot, not an efficacy trial ^[1]. A 2025 narrative review concludes that only three pilot studies have examined BPC-157 in humans, that rigorous large-scale trials are lacking, and that the peptide should be treated as investigational ^[2].

Reported effects, cautions & safety

The safety signal within the tiny human dataset and the animal work is reassuring as far as it goes — but "as far as it goes" is the operative phrase. The absence of long-term, large-sample human safety data means the real-world profile is genuinely unknown ^[2].

Several cautions follow directly from the literature:

• Overwhelmingly preclinical. Most evidence comes from rodents, and a large share of the foundational work originates from a single research group; newer authors explicitly flag this as raising independent-replication questions ^[2].
• Unregulated supply. BPC-157 is not an approved drug anywhere; it is widely distributed through non-regulated channels, so product identity, purity and actual dose are unverified outside formal studies.
• Banned in sport. Prohibited at all times by WADA under the S0 (non-approved substances) category — a direct concern for any competitive athlete ^[2].
• Unsupported online claims. Common claims about weight loss, muscle building, or testosterone increase are not supported by the published evidence and should be treated skeptically ^[2].

No community-anecdote reports appear in this desk's source material for BPC-157 as a standalone compound, so none are presented here; the cautions above are drawn from cited literature.

Where it fits in recovery research

Among the four entries on this desk, BPC-157 is the lead and the most broadly studied — but breadth is not depth. Its animal record spans tendon, gut, muscle and nerve repair, unified by an angiogenesis-forward mechanism, while its human file remains three small pilots ^[2]. Read alongside TB-500, which approaches repair through actin-driven cell migration, and GHK-Cu, which carries the strongest human (topical) data, BPC-157 illustrates the central tension of this field: a coherent, decades-deep preclinical signal that has barely crossed into controlled human work. See the comparison page for how it lines up against the others.